Vivaldi Coelho Rogerio

CIK 00016103816 companiesSAN DIEGO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001610381

Recent Transactions

50 trades

Disposition to Issuer
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2026-09-01$85.00/sh−13,300→ 5,925 total
Disposition to Issuer
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2026-09-01$85.00/sh−5,925→ 0 total
Disposition to Issuer
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (Right to Buy)
2026-09-01$56.69/sh−35,000→ 0 total
Disposition to Issuer
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (Right to Buy)
2026-09-01$66.71/sh−8,750→ 0 total
Disposition to Issuer
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (Right to Buy)
2026-09-01$64.68/sh−17,500→ 0 total
Disposition to Issuer
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (Right to Buy)
2026-09-01$40.29/sh−12,500→ 0 total
Disposition to Issuer
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (Right to Buy)
2026-09-01$52.67/sh−10,350→ 0 total
Disposition to Issuer
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (Right to Buy)
2026-09-01$49.13/sh−9,730→ 0 total
Sale
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2026-07-02$40.00/sh−3,000→ 19,225 total
Award
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (Right to Buy)
2026-06-18+9,730→ 9,730 total
Award
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2026-06-18+5,925→ 22,225 total
Sale
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2026-03-12$36.77/sh−523→ 16,300 total
Sale
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2026-03-12$36.08/sh−4,477→ 16,823 total
Exercise/Conversion
Viatris Inc$VTRS
Restricted Stock Units
2026-03-06−23,660→ 0 total
Exercise/Conversion
Viatris Inc$VTRS
Common Stock
2026-03-06+23,660→ 45,351 total
Exercise/Conversion
Viatris Inc$VTRS
Common Stock
2026-03-06+1,175→ 46,526 total
Exercise/Conversion
Viatris Inc$VTRS
Dividend Equivalent Units
2026-03-06−1,174.492→ 0 total
Award
Viatris Inc$VTRS
Restricted Stock Units
2026-03-06+15,890→ 15,890 total
Award
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2025-06-11+6,900→ 21,300 total
Award
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (right to buy)
2025-06-11+10,350→ 10,350 total
Award
Viatris Inc$VTRS
Restricted Stock Units
2025-03-06+23,660→ 23,660 total
Exercise/Conversion
Viatris Inc$VTRS
Dividend Equivalent Units
2025-03-04−423.013→ 0 total
Exercise/Conversion
Viatris Inc$VTRS
Common Stock
2025-03-04+21,267→ 21,267 total
Exercise/Conversion
Viatris Inc$VTRS
Common Stock
2025-03-04+424→ 21,691 total
Exercise/Conversion
Viatris Inc$VTRS
Restricted Stock Units
2025-03-04−21,267→ 0 total
Award
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (right to buy)
2024-06-07+12,500→ 12,500 total
Award
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2024-06-07+3,400→ 14,400 total
Award
Viatris Inc$VTRS
Restricted Stock Units
2024-06-03+21,267→ 21,267 total
Disposition to Issuer
Sigilon Therapeutics, Inc.
Common Stock
2023-08-11−12,169→ 0 total
Disposition to Issuer
Sigilon Therapeutics, Inc.
Stock Option (Right to Buy)
2023-08-11$0.75/sh−35,382→ 0 total
Exercise/Conversion
Sigilon Therapeutics, Inc.
Stock Option (Right to Buy)
2023-07-21−5,528→ 12,163 total
Exercise/Conversion
Sigilon Therapeutics, Inc.
Common Stock
2023-07-21$19.24/sh+5,528→ 11,963 total
Award
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2023-06-16+6,000→ 11,000 total
Award
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (right to buy)
2023-06-16+17,500→ 17,500 total
Purchase
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2023-06-08$22.06/sh+5,000→ 5,000 total
Award
Sigilon Therapeutics, Inc.
Stock Option (Right to Buy)
2023-02-28+460,000→ 460,000 total
Award
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (right to buy)
2022-06-17+8,750→ 8,750 total
Award
Sigilon Therapeutics, Inc.
Stock Option (Right to Buy)
2022-02-18$1.48/sh+230,000→ 230,000 total
Award
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (right to buy)
2022-01-03+25,000→ 25,000 total
Award
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (right to buy)
2022-01-03+35,000→ 35,000 total
Award
Sigilon Therapeutics, Inc.
Stock Option (Right to Buy)
2022-01-03$3.03/sh+400,000→ 400,000 total
Award
Sigilon Therapeutics, Inc.
Common Stock
2021-11-04+50,000→ 73,461 total
Award
Sigilon Therapeutics, Inc.
Stock Option (Right to Buy)
2021-02-11+200,000→ 200,000 total
Conversion
Sigilon Therapeutics, Inc.
Series B Convertible Preferred Stock
2020-12-08−22,222→ 0 total
Conversion
Sigilon Therapeutics, Inc.
Common Stock
2020-12-08+22,222→ 22,222 total
Disposition to Issuer
Bioverativ Inc.
Non-Qualified Stock Option
2018-03-08−113,230→ 0 total
Disposition to Issuer
Bioverativ Inc.
Restricted Stock Units
2018-03-08−42,727→ 0 total
Disposition to Issuer
Bioverativ Inc.
Common Stock
2018-03-08−5,758.041→ 0 total
Disposition to Issuer
Bioverativ Inc.
Restricted Stock Units
2018-03-08−14,230→ 0 total
Disposition to Issuer
Bioverativ Inc.
Non-Qualified Stock Option
2018-03-08−56,615→ 0 total

Companies

Recent Filings

Address

C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD

SAN DIEGO, CA, 92121

View on SEC.gov